Co-Diagnostics withdrew its 510(k) application for its COVID-19 test to submit an enhanced version addressing shelf-life stability concerns. The new submission will incorporate platform improvements, ...

Co-Diagnostics ( (CODX)) has shared an update. On January 7, 2026, Co-Diagnostics received notice from Nasdaq that its common stock would be delisted from the Nasdaq Capital Market for continued ...

) has been revised to $1.28 / share. This is a decrease of 37.50% from the prior estimate of $2.04 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...

CO-DIAGNOSTIC ($CODX) posted quarterly earnings results on Thursday, March 27th. The company reported earnings of -$0.36 per share, missing estimates of -$0.35 by $0. ...

CO-DIAGNOSTIC ($CODX) is expected to release its quarterly earnings data on Thursday, March 27th after market close, per Finnhub. Analysts are expecting revenue of ...

The company's stock, which was trading at $6.13 in April 2022, is now trading at $1.35, a ~77% discount. It has multiple products but none have reported meaningful revenues to make up for its ...

CoDiagnostics CODX recently announced that the Australian Patent Office has granted a patent covering its new Co-Dx PCR platform, marking the first patent issued for this point-of-care technology.

Co-Diagnostics (NASDAQ:CODX) just reported results for the first quarter of 2024. Co-Diagnostics reported earnings per share of -31 cents. This was below the analyst estimate for EPS of -21 cents. The ...